All In Biotech

NDA 020788 · Organon

Propecia

Finasteride · Oral · 5-alpha Reductase Inhibitor

Last checked: Nov 20, 2026Latest source record: Aug 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Dec 19, 1997

Approved uses

2

Original approval plus efficacy supplements

Registered trials

78

20 Phase 3, 6 recruiting

FAERS reports

53,674

34,283 serious, 4,371 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 14, 2024.

PROPECIA ® is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY . Efficacy in bitemporal recession has not been established. PROPECIA is not indicated for use in women. PROPECIA is a 5α-reductase inhibitor indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY ( 1 ). PROPECIA is not indicated for use in women ( 1 , 4 , 5.1 ).

Mechanism: Finasteride is a competitive and specific inhibitor of Type II 5α-reductase, an intracellular enzyme that converts the androgen testosterone into DHT. Two distinct isozymes are found in mice, rats, monkeys, and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and developmental stages. In humans, Type I 5α-reductase is predominant in the sebaceous glands of most regions of skin, including scalp, and liver. Type I 5α-reductase is responsible for approximately one-third of circulating DHT. The Type II 5α-reductase isozyme is primarily found in prostate,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PROPECIA · FINASTERIDE 1MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Finasteride" as an intervention, any sponsor and status, largest first.

All 78 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • erectile dysfunction4,084
  • fatigue3,692
  • depression3,552
  • anxiety2,953
  • adverse drug reaction2,745
  • sexual dysfunction2,364
  • drug ineffective2,314
  • dizziness2,149
  • diarrhoea2,053
  • death2,003
  • insomnia1,973
  • asthenia1,890

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004249
2005281
2006295
2007311
2008350
2009426
2010639
2011959
20121,492
20131,860
20141,882
20152,657
20162,905
20172,889
20183,540
20193,387
20203,835
20213,282
20223,038
20232,914
20244,912
20257,185
20264,385

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 551 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.